| Drug Name |
Ipratropium bromide monohydrate |
| Drug ID |
BADD_D01193 |
| Description |
Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.[A176957]
Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891] |
| Indications and Usage |
For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
R01AX03; R03BB01 |
| DrugBank ID |
DB00332
|
| KEGG ID |
D02212
|
| MeSH ID |
D009241
|
| PubChem ID |
441337
|
| TTD Drug ID |
D0S0AS
|
| NDC Product Code |
17337-0520 |
| Synonyms |
Ipratropium | (endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane | N-Isopropylatropine | N Isopropylatropine | Atrovent | Ipratropium Bromide Anhydrous | Ipratropium Bromide, (endo,anti)-Isomer | Sch-1178 | Sch 1178 | Sch1178 | Ipratropium Bromide Monohydrate | Ipratropium Bromide, endo-Isomer | Itrop | Sch-1000 | Sch 1000 | Sch1000 | Ipratropium Bromide | Ipratropium Bromide, (exo,syn)-Isomer |
